Quick Hits: Opioid/Benzodiazepine Warning, DEA Set to Ban Supplement & More

Quick Hits: Transvaginal Mesh Pulled, New Weight Loss Drug & More

“Black box” warnings – the strongest the FDA can mandate – will be added to the labeling of prescription opioid drugs and benzodiazepines amid growing concern about side effects when the medications are taken together. An FDA review found cases where people taking both drug classes experienced serious side effects, including slowed or difficulty breathing, and even death. Both opioids, which are used to treat pain, and benzodiazepines, which are tranquilizers, depress the body’s central nervous system. The agency is also advising health care professionals to limit prescribing of opioids and benzodiazepines together only to patients for whom no other alternatives are available. Posted August 31, 2016. Via FDA.

The DEA is set to ban kratom, a plant-derived drug currently sold as a dietary supplement, over concerns it is addicting and has no medicinal value. The DEA wants to list kratom as a schedule I drug under the Controlled Substances Act, putting it in the same class as heroin and LSD. Kratom is known for its sedative properties, and has even been used by some as a pain reliever. There have also been anecdotal reports of people using kratom to come off dependence on prescription opioids or heroin. However, in July, the CDC noted that kratom can be abused, and between 2010 and 2015, poison control centers received more than 660 calls related to kratom. Posted August 31, 2016. Via Federal Register.

The FDA has approved a biosimilar version of the autoimmune disease treatment Enbrel (etanercept). The approval is only the second time the agency has approved a biosimilar – in essence, a generic version – of a biologic based drug, which can costs tens of thousands of dollars per year. Like Enbrel, Erelzi (etanercept-szzs) is indicated to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and plaque psoriasis. Posted August 30, 2016. Via FDA.


Jonathan Block

Jonathan Block

Jonathan Block is an associate editor at BioCentury, which provides news and information about the biotechnology and pharmaceutical industries. Prior to joining BioCentury in 2019, Jonathan worked for MedShadow as content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?

No votes so far! Be the first to rate this post.


Latest News

Diabetes, Fertility Supplements, Nootropics

Diabetes, Fertility Supplements, Nootropics

Supplements are sold without review or approval of the FDA. They are not allowed to make specific health claims, but general ones, such as “improves well-being” and “boosts energy” are legal.  That leaves the door open for unscrupulous, or careless, manufacturers. The FDA also does not regulate the manufacturers recommended…

Vitamin E, the Source of Mystery Vaping Illness

Vitamin E, the Source of Mystery Vaping Illness

A “breakthrough” in the investigation of vaping illness and death, EVALI, has been announced by Federal health officials and the CDC (Centers for Disease Control).

  • Advertisement